CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | long-chain fatty acid |
|
Accession: | CHEBI:15904
|
browse the term
|
Definition: | A fatty acid with a chain length ranging from C13 to C22. |
Synonyms: | related_synonym: | Formula=CHO2R; Higher fatty acid; LCFA; LCFAs; SMILES=OC([*])=O; long-chain fatty acids |
| alt_id: | CHEBI:13655; CHEBI:14529; CHEBI:25075; CHEBI:6528 |
| xref: | KEGG:C00638 |
| cyclic_relationship: | is_conjugate_acid_of CHEBI:57560 |
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein |
CTD |
PMID:17056761 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:21724996 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein] |
CTD |
PMID:21724996 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein] |
CTD |
PMID:21724996 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] |
CTD |
PMID:21724996 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] |
CTD |
PMID:21724996 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21724996 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:21724996 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid binds to and affects the activity of PPARG protein |
CTD |
PMID:17056761 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein] |
CTD |
PMID:21724996 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases secretion |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein |
CTD |
PMID:17056761 PMID:21724996 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
docosapentaenoic acid affects the expression of CRP protein |
CTD |
PMID:22113248 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
docosapentaenoic acid inhibits the reaction [Ethanol results in decreased expression of PLA2G6 protein] |
CTD |
PMID:25029343 |
|
NCBI chr 7:120,519,479...120,559,716
Ensembl chr 7:120,519,467...120,559,347
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
EXP |
docosapentaenoic acid results in decreased expression of PTGS2 protein docosapentaenoic acid inhibits the reaction [Dimethoate results in increased expression of PTGS2 protein] |
CTD |
PMID:22476691 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
docosapentaenoic acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases abundance increases chemical synthesis |
EXP ISO |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:18984061 PMID:21193584 PMID:23872364 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2849922 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases chemical synthesis |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15613483 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases activity |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of EPHX2 protein |
CTD |
PMID:25600587 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] |
CTD |
PMID:15613483 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions affects activity |
EXP |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein |
CTD |
PMID:18984061 |
|
NCBI chr 4:159,077,195...159,079,003
Ensembl chr 4:159,077,195...159,079,003
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNB1 protein |
CTD |
PMID:18984061 |
|
NCBI chr 3:163,850,785...163,935,610
Ensembl chr 3:163,850,785...163,935,617
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNC4 protein |
CTD |
PMID:18984061 |
|
NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:143,448,318...143,453,544
Ensembl chr 7:143,448,318...143,453,544
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinine co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:25600587 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:25600587 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity affects localization multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15451026 PMID:23355332 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPA mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPB mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid binds to and results in increased activity of PPARD protein |
CTD |
PMID:12069687 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases activity affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein |
CTD |
PMID:15451026 PMID:15613483 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein |
CTD |
PMID:23355332 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:22,597,103...22,619,968
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolenin results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolenin results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:86,345,946...86,560,694
Ensembl chr14:86,345,953...86,560,694
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
trilinolenin results in decreased expression of SCD1 mRNA |
CTD |
PMID:8729090 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolein results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolein results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:86,345,946...86,560,694
Ensembl chr14:86,345,953...86,560,694
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions decreases expression |
ISO |
Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14769825 PMID:17550345 PMID:20103642 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:10698703 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein |
CTD |
PMID:19646460 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of BCAR1 protein |
CTD |
PMID:11792571 |
|
NCBI chr19:43,932,543...43,967,452
Ensembl chr19:43,932,554...43,955,783
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein |
CTD |
PMID:23251428 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
C5 |
complement C5 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of HC protein |
CTD |
PMID:25822713 |
|
NCBI chr 3:14,049,993...14,113,931 NCBI chr 3:14,206,466...14,229,141
Ensembl chr 3:14,049,995...14,229,080
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] |
CTD |
PMID:23251428 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccl12 |
chemokine (C-C motif) ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:69,476,866...69,478,416
Ensembl chr10:69,476,775...69,478,462
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:52,379,341...52,403,979
Ensembl chr 2:52,379,341...52,404,246
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:24706986 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of CSF1 protein |
CTD |
PMID:25822713 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:57,060,005...57,064,600
Ensembl chr10:57,060,007...57,064,600
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA |
CTD |
PMID:16224106 |
|
NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
multiple interactions |
ISO |
DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 7:3,143,826...3,170,764
Ensembl chr 7:3,143,827...3,170,146
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions decreases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 PMID:25896349 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr X:15,273,937...15,281,759
Ensembl chr X:15,378,789...15,382,066
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr10:97,647,196...97,680,030
Ensembl chr10:97,647,111...97,684,730
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein |
CTD |
PMID:17919812 PMID:22537771 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation |
EXP |
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:20864298 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
lysophosphatidic acid results in increased secretion of IL6 protein |
CTD |
PMID:21821728 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6st |
interleukin 6 signal transducer |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:44,279,199...44,319,427
Ensembl chr 2:44,289,393...44,314,944
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,704,866...3,941,215
Ensembl chr18:3,705,916...3,940,838
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:112,031,614...112,073,187
Ensembl chr13:112,031,594...112,073,186
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
increases response to substance multiple interactions |
ISO |
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] |
CTD |
PMID:16224106 PMID:16809448 PMID:25398768 |
|
NCBI chr 5:75,557,038...75,678,067
Ensembl chr 5:75,557,042...75,676,584
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
multiple interactions |
ISO |
lysophosphatidic acid binds to and results in increased activity of LPAR6 protein |
CTD |
PMID:18297070 |
|
NCBI chr15:55,126,953...55,128,762
Ensembl chr15:55,126,953...55,128,761
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
lysophosphatidic acid results in increased phosphorylation of MTOR protein |
CTD |
PMID:14769825 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
ISO |
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:24587105 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
ISO |
MYLK protein affects the susceptibility to lysophosphatidic acid |
CTD |
PMID:10640419 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 |
CTD |
PMID:25398768 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] |
CTD |
PMID:15081308 PMID:25449040 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 2:196,227,669...196,270,949
Ensembl chr 2:196,227,670...196,270,826
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:11243883 PMID:14769825 |
|
NCBI chr 2:113,651,967...113,849,403
Ensembl chr 2:113,652,348...113,849,403
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP |
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:51,404,971...51,515,382
Ensembl chr 7:51,404,919...51,515,373
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 PMID:11792571 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of PTK2B protein |
CTD |
PMID:11792571 |
|
NCBI chr15:42,827,306...42,947,796
Ensembl chr15:42,827,310...42,947,656
|
|
G |
Rhoa |
ras homolog family member A |
increases activity multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] |
CTD |
PMID:15081308 PMID:24587105 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions increases activity |
ISO |
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] |
CTD |
PMID:24587105 |
|
NCBI chr 2:207,271,692...207,278,010
Ensembl chr 2:207,271,853...207,279,314
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14769825 PMID:17919812 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] |
CTD |
PMID:17919812 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:226,297,013...226,353,712
Ensembl chr 1:226,297,016...226,353,611
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:13,113,073...13,157,748
Ensembl chr12:13,113,237...13,157,666
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:76,375,981...76,408,224
Ensembl chr10:76,386,471...76,407,989
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:234,478,908...234,631,264
Ensembl chr 1:234,479,289...234,596,971
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid] |
CTD |
PMID:20933508 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Tbxas1 |
thromboxane A synthase 1 |
multiple interactions |
ISO |
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid |
CTD |
PMID:2572437 |
|
NCBI chr 4:66,624,181...66,846,745
Ensembl chr 4:66,670,618...66,846,805
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA] |
CTD |
PMID:21094227 PMID:21735453 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA] |
CTD |
PMID:21735453 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein] |
CTD |
PMID:21735453 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO EXP |
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein] |
CTD |
PMID:12721327 PMID:15528449 PMID:16256979 |
|
NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:25619643 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E] which results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 |
CTD |
PMID:25619643 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
affects metabolic processing |
ISO |
GSTA1 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
affects metabolic processing |
ISO |
GSTA4 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
EXP |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein |
CTD |
PMID:27428043 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] |
CTD |
PMID:27428043 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions increases cleavage |
EXP ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] |
CTD |
PMID:27428043 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16286479 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases chemical synthesis multiple interactions |
ISO |
CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:12675279 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases abundance |
ISO |
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:19896470 PMID:22680237 PMID:24472606 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein |
CTD |
PMID:16286479 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19464254 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19464254 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16286479 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions |
ISO |
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:28694203 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases chemical synthesis |
ISO |
HPGD protein results in increased chemical synthesis of 15-ketoprostaglandin E2 |
CTD |
PMID:20448048 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions increases metabolic processing increases reduction |
EXP ISO |
15-ketoprostaglandin E2 inhibits the reaction [PTGR1 protein results in increased reduction of 10-nitro-oleic acid analog]; Dithionitrobenzoic Acid inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]; Indomethacin inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2] [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:23878198 PMID:25619643 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects export affects glutathionylation increases transport |
ISO |
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:14979731 PMID:21728338 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects export |
ISO |
ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog |
CTD |
PMID:14979731 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:19997560 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:15498850 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] |
CTD |
PMID:15187150 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein |
CTD |
PMID:15254749 PMID:15729575 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein |
CTD |
PMID:15729575 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:15498850 PMID:22245093 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] |
CTD |
PMID:12604364 PMID:14998300 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of DDX58 mRNA] |
CTD |
PMID:16303604 |
|
NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] |
CTD |
PMID:12468449 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12021203 PMID:16573735 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA] |
CTD |
PMID:11457450 PMID:11687581 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein |
CTD |
PMID:21728338 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression decreases expression multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15254749 PMID:15994020 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTA3 mRNA |
CTD |
PMID:14652005 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] |
CTD |
PMID:14979731 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein] |
CTD |
PMID:11600134 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects stability multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein] |
CTD |
PMID:17658243 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein |
CTD |
PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
ISO |
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15618017 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein |
CTD |
PMID:16299251 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression decreases secretion |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein |
CTD |
PMID:12847270 PMID:16844232 PMID:19888466 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] |
CTD |
PMID:14998300 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein |
CTD |
PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA |
CTD |
PMID:15751073 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:23688403 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:12604364 PMID:12847270 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] |
CTD |
PMID:14625208 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] |
CTD |
PMID:11457450 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Lep |
leptin |
multiple interactions increases secretion |
ISO |
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein |
CTD |
PMID:11092516 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA |
CTD |
PMID:12021203 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] |
CTD |
PMID:16324150 |
|
NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] |
CTD |
PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] |
CTD |
PMID:19997048 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nes |
nestin |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein |
CTD |
PMID:15212945 |
|
NCBI chr 2:187,343,109...187,352,972
Ensembl chr 2:187,344,056...187,352,969
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein] |
CTD |
PMID:19136476 PMID:21728338 PMID:22245093 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases localization |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein |
CTD |
PMID:11457450 PMID:16299251 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15498850 PMID:22245093 PMID:23688403 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 PMID:16461118 PMID:19997048 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein |
CTD |
PMID:11890746 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects activity multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein] |
CTD |
PMID:15187150 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] |
CTD |
PMID:22245093 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:23973622 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA |
CTD |
PMID:9518257 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein |
CTD |
PMID:9013583 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein |
CTD |
PMID:17341418 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases response to substance increases expression increases activity multiple interactions decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein |
CTD |
PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14625208 PMID:14979731 PMID:14998300 PMID:15212945 PMID:15254749 PMID:15322177 PMID:15491415 PMID:15707588 PMID:15729575 PMID:15866424 PMID:15994020 PMID:16324150 PMID:16499875 PMID:17341418 PMID:18278065 PMID:18485432 PMID:19922793 PMID:23943857 PMID:26172262 PMID:30138673 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,195,606...19,196,508
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:12721327 PMID:16256979 |
|
NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:17439952 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2 |
CTD |
PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
increases phosphorylation |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein |
CTD |
PMID:12584205 |
|
NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB |
CTD |
PMID:12839938 PMID:15254749 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein] |
CTD |
PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:152,078,217...152,122,684
Ensembl chr 5:152,078,220...152,122,684
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA |
CTD |
PMID:15254749 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12584205 PMID:12847270 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:12584205 PMID:12847270 PMID:19922793 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions decreases expression |
ISO |
PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] |
CTD |
PMID:16499875 |
|
NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:16611854 PMID:18278065 PMID:19429239 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein |
CTD |
PMID:15212945 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA |
CTD |
PMID:20174873 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:12604364 PMID:19888466 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM |
CTD |
PMID:15254749 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:140,448,284...140,466,159
Ensembl chr 7:140,448,465...140,454,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein |
CTD |
PMID:15498850 PMID:16299251 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of HMOX1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases activity |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of NQO1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases metabolic processing multiple interactions |
ISO |
PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:146,630,298...146,690,375
Ensembl chr 3:146,630,299...146,690,375
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:18,647,903...18,695,133
Ensembl chr15:18,647,844...18,695,133
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:31024316 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:11,490,852...11,499,287
Ensembl chr 7:11,490,852...11,499,282
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:30301768 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
EXP |
2-bromopalmitate results in decreased expression of APOA1 mRNA |
CTD |
PMID:7556148 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of CEBPB mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
2-bromopalmitate results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases activity |
EXP |
2-bromopalmitate results in increased activity of GAPDH protein |
CTD |
PMID:10650946 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of IFIT3 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 1:252,906,234...252,911,377
Ensembl chr 1:252,906,234...252,911,382
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of IRF1 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
decreases expression |
ISO |
2-bromopalmitate results in decreased expression of LAT2 protein |
CTD |
PMID:23001822 |
|
NCBI chr12:25,114,099...25,128,381
Ensembl chr12:25,119,355...25,125,749
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
2-bromopalmitate results in increased expression of LDLR mRNA |
CTD |
PMID:23150725 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
2-bromopalmitate results in increased expression of LRAT mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 2:181,896,304...181,905,366
Ensembl chr 2:181,896,305...181,905,300
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of LY6E mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 7:116,355,426...116,359,862
Ensembl chr 7:116,355,698...116,359,862
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in decreased expression of MPO mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases activity multiple interactions |
ISO |
2-bromopalmitate results in increased activity of PPARD protein 2-bromopalmitate results in increased activity of [RXRA protein binds to PPARD protein] |
CTD |
PMID:15997096 PMID:21543282 PMID:23150725 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
2-bromopalmitate results in increased expression of PPARG protein |
CTD |
PMID:10650946 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
2-bromopalmitate binds to and results in increased expression of RARA protein; 2-bromopalmitate inhibits the reaction [Am 580 results in decreased expression of RARA protein]; 2-bromopalmitate inhibits the reaction [Tretinoin results in decreased expression of RARA protein]; [2-bromopalmitate results in increased susceptibility to Tretinoin] which results in increased expression of RARA protein |
CTD |
PMID:30076181 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of RARB mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases expression |
EXP |
2-bromopalmitate results in increased expression of RBP1 mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 8:106,449,321...106,470,842
Ensembl chr 8:106,449,321...106,470,842
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
2-bromopalmitate results in increased activity of [RXRA protein binds to PPARD protein] |
CTD |
PMID:15997096 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Spi1 |
Spi-1 proto-oncogene |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of SPI1 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:79,918,127...79,937,708
Ensembl chr 3:79,918,969...79,938,301
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
2-bromopalmitate promotes the reaction [Tretinoin results in increased expression of TGM2 mRNA] |
CTD |
PMID:30076181 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
EXP |
2-bromopalmitate results in increased expression of UCP2 mRNA |
CTD |
PMID:11341955 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRA protein |
CTD |
PMID:23843199 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Rxrb |
retinoid X receptor beta |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:3,822,673...3,829,138
Ensembl chr20:3,823,042...3,829,140
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects binding |
ISO |
2-hydroxyphytanic acid binds to RXRG protein |
CTD |
PMID:23843199 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
|
G |
Mgll |
monoglyceride lipase |
increases degradation multiple interactions |
EXP |
MGLL protein results in increased degradation of 2-oleoylglycerol Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol] |
CTD |
PMID:19515121 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
|
G |
Clock |
clock circadian regulator |
affects abundance |
ISO |
CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:22440902 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:11124159 PMID:12388396 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA |
CTD |
PMID:22442195 |
|
NCBI chr 5:134,196,910...134,207,888
Ensembl chr 5:134,196,912...134,207,863
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
multiple interactions increases localization |
ISO EXP |
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] |
CTD |
PMID:16055480 |
|
NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP |
N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:18067589 PMID:19458537 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:22,597,103...22,619,968
|
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases secretion |
ISO |
5-oxo-6,8,11,14-eicosatetraenoic acid results in increased secretion of CSF2 protein |
CTD |
PMID:15136573 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
|
G |
Agt |
angiotensinogen |
increases abundance multiple interactions |
EXP |
AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:21193584 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Apoe |
apolipoprotein E |
increases abundance multiple interactions |
ISO |
APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:14966570 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Avp |
arginine vasopressin |
increases abundance multiple interactions |
EXP |
AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects abundance multiple interactions |
ISO EXP |
BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha [kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16514058 PMID:29775649 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases abundance increases abundance |
ISO EXP |
CALCA protein alternative form results in decreased abundance of 6-Ketoprostaglandin F1 alpha CALCA protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:12024109 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions increases abundance |
ISO |
7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:25339356 |
|
NCBI chr16:50,151,127...50,175,407
Ensembl chr16:50,152,008...50,175,458
|
|
G |
Kng2 |
kininogen 2 |
increases abundance multiple interactions |
EXP |
KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 PMID:29775649 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ptgis |
prostaglandin I2 synthase |
multiple interactions increases chemical synthesis |
EXP |
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha PTGIS protein results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:163,950,746...163,986,129
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; PTGS2 gene mutant form inhibits the reaction [[Nanotubes, Carbon co-treated with OVAL protein] results in increased abundance of 6-Ketoprostaglandin F1 alpha]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 PMID:23642096 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tnf |
tumor necrosis factor |
increases abundance |
ISO |
TNF protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:1993070 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions increases chemical synthesis |
ISO |
Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects hydrolysis |
ISO |
EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:28975360 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
affects response to substance |
ISO |
PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 |
CTD |
PMID:22565502 |
|
NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
|
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:17118406 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:22610977 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance increases chemical synthesis |
ISO EXP |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:11530235 PMID:16529823 PMID:19751497 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
affects metabolic processing multiple interactions |
ISO |
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:18024956 |
|
NCBI chr 5:152,606,850...152,635,956
Ensembl chr 5:152,606,847...152,634,803
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha |
CTD |
PMID:8621535 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions affects response to substance |
ISO |
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha |
CTD |
PMID:18158556 PMID:22565502 |
|
NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
eleostearic acid results in decreased expression of BCL2 protein |
CTD |
PMID:15961301 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
eleostearic acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein]; eleostearic acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] eleostearic acid results in decreased activity of CAT protein |
CTD |
PMID:20851731 PMID:21382362 PMID:22269903 PMID:23422533 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
eleostearic acid results in increased expression of GADD45A protein |
CTD |
PMID:15961301 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
eleostearic acid inhibits the reaction [methylmercuric chloride results in increased activity of GPT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
eleostearic acid results in decreased activity of GSR protein |
CTD |
PMID:23422533 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
eleostearic acid results in increased expression of PPARG mRNA; eleostearic acid results in increased expression of PPARG protein |
CTD |
PMID:15961301 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
eleostearic acid results in increased expression of TP53 protein |
CTD |
PMID:15961301 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of ADIPOR1 mRNA |
CTD |
PMID:17408517 |
|
NCBI chr13:51,240,470...51,260,233
Ensembl chr13:51,240,911...51,260,228
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:17408517 |
|
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Cd68 |
Cd68 molecule |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of CD68 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of CYCS protein |
CTD |
PMID:17408517 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
decreases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in decreased expression of FMO3 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of GSR protein |
CTD |
PMID:17408517 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Insr |
insulin receptor |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of INSR protein |
CTD |
PMID:17327424 |
|
NCBI chr12:1,682,527...1,816,414
Ensembl chr12:1,680,957...1,816,414
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP ISO |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in decreased phosphorylation of IRS1 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA] |
CTD |
PMID:17327424 PMID:17408517 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K1 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K1 protein |
CTD |
PMID:17869086 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
multiple interactions |
EXP |
[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased phosphorylation of and results in increased activity of MAP2K3 protein; cis-9, trans-11-conjugated linoleic acid results in increased phosphorylation of and results in increased activity of MAP2K3 protein |
CTD |
PMID:17869086 |
|
NCBI chr10:45,089,455...45,110,802
Ensembl chr10:47,182,433...47,203,753
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of ME1 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of NFKB1 protein |
CTD |
PMID:17327424 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of NFKB2 protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of NR1H3 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Por |
cytochrome p450 oxidoreductase |
decreases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in decreased expression of POR mRNA |
CTD |
PMID:17217560 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA mRNA; [trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased expression of PPARA protein |
CTD |
PMID:17408517 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of REL protein |
CTD |
PMID:17327424 |
|
NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of and affects the activity of RELA protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
affects activity |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the activity of RELB protein |
CTD |
PMID:17327424 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of SCD1 mRNA |
CTD |
PMID:17217560 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression multiple interactions |
ISO |
cis-9, trans-11-conjugated linoleic acid results in increased expression of SLC2A4 protein cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:17327424 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
[trans-10,cis-12-conjugated linoleic acid co-treated with cis-9, trans-11-conjugated linoleic acid] results in increased activity of SOD2 protein |
CTD |
PMID:17408517 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid affects the expression of SREBF1 mRNA |
CTD |
PMID:17327424 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression |
ISO |
cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of IRS1 mRNA]; cis-9, trans-11-conjugated linoleic acid inhibits the reaction [TNF protein results in decreased expression of SLC2A4 mRNA] cis-9, trans-11-conjugated linoleic acid affects the expression of TNF mRNA |
CTD |
PMID:17327424 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Adtrp |
androgen-dependent TFPI-regulating protein |
affects chemical synthesis |
ISO |
ADTRP protein affects the chemical synthesis of 9-hydroxystearic acid |
CTD |
PMID:32152231 |
|
NCBI chr17:22,619,913...22,688,296
Ensembl chr17:22,619,891...22,688,307
|
|
G |
Aig1 |
androgen-induced 1 |
affects chemical synthesis |
ISO |
AIG1 protein affects the chemical synthesis of 9-hydroxystearic acid |
CTD |
PMID:32152231 |
|
NCBI chr 1:7,816,841...8,038,805
Ensembl chr 1:7,816,838...8,038,665
|
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
9,11-linoleic acid results in increased expression of CD36 mRNA |
CTD |
PMID:18155510 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization |
ISO |
9,11-linoleic acid affects the localization of FOXO1 protein |
CTD |
PMID:15992797 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding |
ISO |
9,11-linoleic acid binds to PPARA protein |
CTD |
PMID:23843199 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
9,11-linoleic acid binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases activity |
ISO |
9,11-linoleic acid binds to PPARG protein 9,11-linoleic acid results in increased activity of PPARG protein |
CTD |
PMID:18155510 PMID:23843199 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
9,11-linoleic acid results in increased phosphorylation of and affects the localization of TP53 protein |
CTD |
PMID:15992797 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] |
CTD |
PMID:14613874 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] |
CTD |
PMID:19014389 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15231676 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin] |
CTD |
PMID:25940438 |
|
NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:19063610 PMID:19162293 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
adrenic acid binds to and results in increased activity of RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid |
CTD |
PMID:30258081 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Cat |
catalase |
increases activity |
EXP |
retinol palmitate results in increased activity of CAT protein |
CTD |
PMID:20679000 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression |
ISO |
retinol palmitate results in increased expression of CYP3A11 mRNA |
CTD |
PMID:19686701 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
retinol palmitate promotes the reaction [EP300 protein binds to MMP9 protein] |
CTD |
PMID:17164434 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
retinol palmitate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:17377406 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
retinol palmitate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein] |
CTD |
PMID:17377406 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases hydrolysis multiple interactions |
ISO |
LIPE protein results in increased hydrolysis of retinol palmitate PLIN3 protein inhibits the reaction [LIPE protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
EXP |
retinol palmitate promotes the reaction [EP300 protein binds to MMP9 protein]; retinol palmitate promotes the reaction [RARA protein binds to MMP9 protein] retinol palmitate results in increased expression of MMP9 mRNA |
CTD |
PMID:17164434 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
PLIN3 protein inhibits the reaction [LIPE protein results in increased hydrolysis of retinol palmitate]; PLIN3 protein inhibits the reaction [PNPLA4 protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr 9:10,769,739...10,781,659
Ensembl chr 9:10,773,901...10,781,109
|
|
G |
Pnpla4 |
patatin like phospholipase domain containing 4 |
increases hydrolysis multiple interactions |
ISO |
PNPLA4 protein results in increased hydrolysis of retinol palmitate PLIN3 protein inhibits the reaction [PNPLA4 protein results in increased hydrolysis of retinol palmitate] |
CTD |
PMID:16741517 |
|
NCBI chr X:45,519,406...45,522,988
Ensembl chr X:45,519,228...45,522,665
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
EXP |
retinol palmitate promotes the reaction [RARA protein binds to MMP9 protein] |
CTD |
PMID:17164434 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
increases expression |
EXP |
retinol palmitate results in increased expression of SCARB1 mRNA |
CTD |
PMID:17299104 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
alpha-Linolenic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of ACACA mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of ACLY mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
Bche |
butyrylcholinesterase |
increases expression increases secretion |
ISO |
alpha-Linolenic Acid results in increased expression of BCHE mRNA alpha-Linolenic Acid results in increased secretion of BCHE protein |
CTD |
PMID:27106529 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of CCL2 protein]] |
CTD |
PMID:29423081 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of CEBPB mRNA |
CTD |
PMID:14563831 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
alpha-Linolenic Acid results in increased expression of CPT1A mRNA |
CTD |
PMID:15307955 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein] |
CTD |
PMID:30672636 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:16978661 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alpha-Linolenic Acid inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:19667161 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions decreases activity |
ISO |
CYP2C9 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] alpha-Linolenic Acid results in decreased activity of CYP2C9 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions decreases activity |
ISO |
CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] alpha-Linolenic Acid results in decreased activity of CYP2C19 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP2E1 protein |
CTD |
PMID:16978661 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:16978661 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
alpha-Linolenic Acid results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
[[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [[alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA] which affects the abundance of Fatty Acids, Unsaturated; [alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA; [alpha-Linolenic Acid co-treated with Testosterone] results in decreased expression of FADS1 mRNA; fulvestrant inhibits the reaction [[alpha-Linolenic Acid co-treated with Estradiol] results in increased expression of FADS1 mRNA] |
CTD |
PMID:19576517 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity increases expression |
ISO |
alpha-Linolenic Acid results in increased activity of GCLC protein alpha-Linolenic Acid results in increased expression of GCLC mRNA |
CTD |
PMID:17092368 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [methylmercuric chloride results in increased activity of GPT protein] |
CTD |
PMID:22269903 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression multiple interactions |
ISO |
alpha-Linolenic Acid results in increased expression of GSTA1 mRNA NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] |
CTD |
PMID:28555106 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
alpha-Linolenic Acid results in increased expression of HMOX1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:17092368 PMID:30672636 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IFNG protein]] |
CTD |
PMID:29423081 PMID:30672636 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in increased expression of IL1B protein alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein] |
CTD |
PMID:16305726 PMID:30672636 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with alpha-Linolenic Acid] results in decreased expression of IL4 protein |
CTD |
PMID:16305726 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of IL6 mRNA]] |
CTD |
PMID:29423081 PMID:30672636 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
ISO |
alpha-Linolenic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO EXP |
NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [alpha-Linolenic Acid results in increased expression of GSTA1 mRNA] alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]] |
CTD |
PMID:28555106 PMID:30672636 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 mRNA]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of NOS2 protein]] |
CTD |
PMID:29423081 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]] |
CTD |
PMID:30672636 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
alpha-Linolenic Acid binds to and results in increased activity of NR1H2 protein |
CTD |
PMID:16731579 |
|
NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions affects binding |
ISO |
alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] alpha-Linolenic Acid binds to NR1H4 protein |
CTD |
PMID:15307955 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Glucose deficiency co-treated with alpha-Linolenic Acid] results in increased expression of PCK1 mRNA |
CTD |
PMID:8536680 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP ISO |
alpha-Linolenic Acid results in increased expression of PLIN2 mRNA; alpha-Linolenic Acid results in increased expression of PLIN2 protein |
CTD |
PMID:16489205 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects abundance increases expression |
EXP ISO |
alpha-Linolenic Acid binds to and results in increased activity of PPARA protein PPARA protein affects the abundance of alpha-Linolenic Acid alpha-Linolenic Acid results in increased expression of PPARA mRNA alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Calcitriol promotes the reaction [alpha-Linolenic Acid results in increased expression of PPARA mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARA protein; Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of alpha-Linolenic Acid] |
CTD |
PMID:10403814 PMID:16731579 PMID:18154422 PMID:19667161 PMID:23619606 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression multiple interactions |
ISO EXP |
alpha-Linolenic Acid results in increased expression of PPARD mRNA; Calcitriol results in increased expression of [alpha-Linolenic Acid results in increased expression of PPARD mRNA] alpha-Linolenic Acid binds to and results in increased activity of PPARB protein |
CTD |
PMID:16731579 PMID:19667161 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression increases activity multiple interactions |
ISO EXP |
alpha-Linolenic Acid results in increased expression of PPARG mRNA alpha-Linolenic Acid results in increased activity of PPARG protein alpha-Linolenic Acid binds to and results in increased activity of PPARG protein |
CTD |
PMID:16731579 PMID:18154422 PMID:20696231 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression |
ISO EXP |
alpha-Linolenic Acid results in increased expression of PTGS2 mRNA alpha-Linolenic Acid results in increased expression of PTGS2 protein alpha-Linolenic Acid results in decreased expression of PTGS2 mRNA |
CTD |
PMID:14563831 PMID:17092368 PMID:22476691 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions affects binding |
ISO |
alpha-Linolenic Acid binds to and results in increased activity of RXRA protein alpha-Linolenic Acid binds to RXRA protein |
CTD |
PMID:16258897 PMID:16731579 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
alpha-Linolenic Acid results in decreased expression of SREBF1 mRNA |
CTD |
PMID:14563831 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]] |
CTD |
PMID:29423081 PMID:30672636 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
[alpha-Linolenic Acid co-treated with Phorbol 12,13-Dibutyrate] results in increased activity of TRPV1 protein |
CTD |
PMID:17038422 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
EXP |
alpha-Linolenic Acid results in increased expression of UCP2 mRNA |
CTD |
PMID:11341955 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]; alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]]; Particulate Matter inhibits the reaction [alpha-Linolenic Acid inhibits the reaction [[Cholesterol, Dietary co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of VCAM1 protein]] |
CTD |
PMID:29423081 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vdr |
vitamin D receptor |
increases expression multiple interactions |
ISO |
alpha-Linolenic Acid results in increased expression of VDR mRNA [Calcitriol co-treated with alpha-Linolenic Acid] results in increased expression of VDR mRNA |
CTD |
PMID:19667161 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:31024316 PMID:31199905 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:25,161,130...25,168,182
Ensembl chr12:25,161,130...25,168,182
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:31121907 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
increases degradation affects expression multiple interactions |
ISO |
FAAH results in increased degradation of anandamide anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:16131814 PMID:16886060 PMID:20702753 PMID:31121907 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects binding |
EXP |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] |
CTD |
PMID:30232874 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
|